工程 T 細胞市場 - 全球產業規模、佔有率、趨勢、機會和預測（按類型、應用、最終用戶、地區和競爭細分，2020-2030 年）

2024 年全球工程 T 細胞市場價值為 263.1 億美元，預計到 2030 年將達到 1,362.6 億美元，預測期內年複合成長率(CAGR) 為 31.51%。這種成長主要得益於細胞免疫療法的快速進步以及工程化 T 細胞療法在腫瘤學中的日益普及。

工程化 T 細胞療法—特別是嵌合抗原受體 T 細胞 (CAR-T) 和 T 細胞受體 T 細胞 (TCR-T)—利用人體免疫系統辨識並摧毀惡性細胞，從而改變了癌症治療。合成生物學和基因編輯技術的不斷進步顯著提高了這些療法的安全性、有效性和持久性，使其成為治療血液系統惡性腫瘤和實體腫瘤的有希望的解決方案。

監管機構正在加快核准流程並擴大這些療法的適應症，促使生物技術和製藥公司在研發方面投入大量資金。這些投資旨在最佳化治療設計、提高製造效率並擴大工程 T 細胞的臨床應用。患者意識的提高、醫療保健支出的增加以及學術機構和行業利益相關者之間為促進創新而加強的合作進一步支持了市場的成長。

關鍵市場促進因素

免疫療法研究的進展

主要市場挑戰

製造複雜性

主要市場趨勢

擴及實體腫瘤

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球工程T細胞市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（嵌合抗原受體、T 細胞受體、腫瘤浸潤淋巴細胞）
  • 依應用（乳癌、大腸直腸癌、白血病、肺癌、黑色素瘤）
  • 按最終用戶（癌症研究中心、診所、醫院等）
  • 按地區
  • 按公司分類（2024）
• 產品市場圖
  • 按類型
  • 按應用
  • 按最終用戶
  • 按地區

第6章：北美工程T細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲工程T細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙

第8章：亞太工程T細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國

第9章：南美洲工程T細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲工程T細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Amgen Inc
• Athenex, Inc.
• Bellicum Pharmaceuticals Inc
• Bristol-Myers Squibb Co
• Eli Lilly & Co
• Gilead Sciences Inc
• Novartis AG
• Oxford Biomedica PLC
• Pfizer Inc
• Precision BioSciences Inc

第 15 章：策略建議

第16章調查會社について,免責事項

Global Engineered T Cells Market for engineered T cells was valued at USD 26.31 billion in 2024 and is projected to reach USD 136.26 billion by 2030, expanding at a compound annual growth rate (CAGR) of 31.51% during the forecast period. This growth is primarily driven by rapid advancements in cellular immunotherapy and the increasing adoption of engineered T cell therapies in oncology.

Engineered T cell therapies-particularly Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor T cells (TCR-T)-have transformed cancer treatment by leveraging the body's immune system to identify and destroy malignant cells. Ongoing progress in synthetic biology and gene editing has significantly improved the safety, efficacy, and persistence of these therapies, positioning them as a promising solution for both hematologic malignancies and solid tumors.

Regulatory agencies are accelerating the approval processes and broadening indications for these therapies, prompting substantial investments from biotechnology and pharmaceutical companies in research and development. These investments aim to optimize therapeutic design, enhance manufacturing efficiency, and expand the clinical applications of engineered T cells. Market growth is further supported by increasing patient awareness, higher healthcare spending, and strengthening collaborations between academic institutions and industry stakeholders to foster innovation.

Key Market Drivers

Advancements in Immunotherapy Research

Immunotherapy has emerged as a transformative approach in modern medicine, particularly in the treatment of cancer. Engineered T cell therapies, such as CAR-T and TCR-T, have gained significant traction due to their ability to utilize the immune system for targeted therapeutic interventions. These innovations stem from a deeper understanding of immune system mechanisms, enabling the development of highly specialized treatments.

For example, CAR-T cell therapy involves modifying a patient's own T cells to recognize and destroy cancer cells. Since the first CAR-T therapy received regulatory approval in 2017, over 30,000 patients with hematologic cancers have undergone treatment, with some achieving durable remissions lasting a decade or more.

Key Market Challenges

Manufacturing Complexity

The production of engineered T cell therapies is highly complex and requires rigorous quality control protocols. Ensuring T cell viability and functionality throughout the manufacturing process is essential for therapeutic success. Scaling up production to meet increasing demand poses significant challenges, as even minor variations in manufacturing conditions can affect product consistency and treatment outcomes.

Key Market Trends

Expansion into Solid Tumors

While CAR-T therapies have primarily been used to treat hematologic cancers, research is increasingly directed toward expanding their use in solid tumors. Emerging clinical trials are focused on overcoming the unique biological barriers presented by solid tumors, potentially broadening the therapeutic scope of engineered T cells and extending their benefits to a wider patient population.

Key Market Players

• Amgen Inc
• Athenex, Inc.
• Bellicum Pharmaceuticals Inc
• Bristol-Myers Squibb Co
• Eli Lilly & Co
• Gilead Sciences Inc
• Novartis AG
• Oxford Biomedica PLC
• Pfizer Inc
• Precision BioSciences Inc

Report Scope:

In this report, the Global Engineered T Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Engineered T Cells Market, By Type:

• Chimeric Antigen Receptor
• T Cell Receptor
• Tumor-Infiltrating Lymphocytes

Engineered T Cells Market, By Application:

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Melanoma

Engineered T Cells Market, By End-User:

• Cancer Research Centers
• Clinics
• Hospitals
• Others

Engineered T Cells Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Engineered T Cells Market.

Available Customizations:

Global Engineered T Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Engineered T Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 5.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 5.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By End-User
  • 5.3.4. By Region

6. North America Engineered T Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 6.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 6.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Engineered T Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Engineered T Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Engineered T Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User

7. Europe Engineered T Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 7.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 7.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Engineered T Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Engineered T Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. France Engineered T Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Engineered T Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Engineered T Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Engineered T Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 8.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 8.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Engineered T Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. Japan Engineered T Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. India Engineered T Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User
  • 8.3.4. Australia Engineered T Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-User
  • 8.3.5. South Korea Engineered T Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-User

9. South America Engineered T Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 9.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 9.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Engineered T Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Engineered T Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Engineered T Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Engineered T Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 10.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 10.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Engineered T Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Engineered T Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Engineered T Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Amgen Inc
• 14.2. Athenex, Inc.
• 14.3. Bellicum Pharmaceuticals Inc
• 14.4. Bristol-Myers Squibb Co
• 14.5. Eli Lilly & Co
• 14.6. Gilead Sciences Inc
• 14.7. Novartis AG
• 14.8. Oxford Biomedica PLC
• 14.9. Pfizer Inc
• 14.10. Precision BioSciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer